GSK PLC on Thursday announced that the European Commission has authorised Arexvy, its respiratory syncytial virus vaccine, for adults aged 50 to 59 who are at increased risk.
The vaccine immunises patients against lower respiratory tract disease caused by respiratory syncytial virus, with the latest approval based on results from a phase 3 trial.
London-based pharmaceutical company GSK said about 20 million adults between the ages of 50 and 59 in 30 European countries have a medical condition that increases their risk for RSV disease.
Arexvy has been approved in the EU for adults over 60 since June last year. The news follows approval in the US, with other countries - including Japan - expected to grant permission later this year.
GSK shares were up 0.4% at 1,658.30 pence each on Thursday morning in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
